Jun 29, 2024, 03:18
Peter Schmid’s findings on atezolizumab and sacituzumab govitecan for advanced TNBC – ESMO
ESMO shared a post on LinkedIn:
“For ESMO members: Breaking Science in Breast Cancer.
Peter Schmid presents his findings on atezolizumab and sacituzumab govitecan for advanced Triple-negative breast cancer (TNBC).
Explore this video and others from this series on OncologyPRO now.”
Additional information
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59